RxDoctor Payments Data

Mary Kate Cooper, APRN

Family · Jonesboro, ARNPI 1669176251

Payments from drug & device makers

$1,129in general payments, 2019–2025

Across 40 payments — averaging $28.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$224
  • Endo USA, Inc.$220
  • Pfizer$157
  • Sumitomo Pharma America, Inc.$133
  • Medtronic$91
  • Ferring Pharmaceuticals Inc.$61
  • plus $242 from 8 others

What the payments were for

  • Speaking & faculty fees$313%
  • Food & beverage$1,09897%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,129 in reported general payments places this provider in the 70th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$33,034
Medicare patients
326
Services billed
857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron74$39,588
GemtesaVibegron58$28,999
Tamsulosin Hcl294$2,723
Silodosin49$2,498
NitrofurantoinNitrofurantoin Macrocrystal47$2,420
Estradiol23$1,666
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$996
Solifenacin Succinate38$844
Methenamine Hippurate18$488
Finasteride92$448
Alfuzosin Hcl ErAlfuzosin Hcl13$353
Oxybutynin Chloride28$329
Ciprofloxacin Hcl26$314
Cephalexin27$251
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip15$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$133$28,99958 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,103 family providers in Arkansas.

Other family in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →